MACROGENICS, INC. Interest Expense
MACROGENICS, INC. (MGNX) reported Interest Expense of $4.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-14
- MACROGENICS, INC. interest expense for the quarter ending 2026-06-30 was $4.40M, a 448.13% increase year-over-year.
- MACROGENICS, INC. interest expense for the quarter ending 2026-03-31 was $4.89M, a 5272.53% increase year-over-year.
- MACROGENICS, INC. interest expense for the quarter ending 2025-09-30 was $3.34M.
- MACROGENICS, INC. interest expense for the quarter ending 2025-06-30 was $802.00K, a 13266.67% increase year-over-year.
- MACROGENICS, INC. interest expense for fiscal 2024 was $1.11M, a 22.03% decline from fiscal 2023.
- MACROGENICS, INC. interest expense for fiscal 2023 was $1.43M.
- MACROGENICS, INC. interest expense for fiscal 2022 was $0.00.
- MACROGENICS, INC. interest expense for fiscal 2021 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.40M 10-Q · filed 2026-08-14 | $9.29M 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $4.89M 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | $3.34M 10-Q · filed 2025-11-12 | $4.14M derived: sum of 2 quarters · filed 2026-08-14 | $4.24M 10-Q · filed 2025-11-12 | $4.21M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $802.00K 10-Q · filed 2026-08-14 | $894.00K 10-Q · filed 2026-08-14 | $869.00K derived: sum of 3 quarters · filed 2026-08-14 | $869.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $91.00K 10-Q · filed 2026-05-13 | $67.00K derived: sum of 2 quarters · filed 2026-05-13 | $67.00K derived: sum of 3 quarters · filed 2026-05-13 | $73.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$24.00K derived: sum of 2 quarters · filed 2025-11-12 | -$18.00K derived: sum of 3 quarters · filed 2025-11-12 | $1.11M 10-K · filed 2025-03-20 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $6.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.14M 10-Q · filed 2025-11-12 | $1.14M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $6.00K 10-Q · filed 2025-08-14 | $1.14M 10-Q · filed 2025-08-14 | $1.14M derived: sum of 3 quarters · filed 2025-08-14 | $1.14M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.13M 10-Q · filed 2025-05-13 | $1.13M derived: sum of 2 quarters · filed 2025-05-13 | $1.13M derived: sum of 3 quarters · filed 2025-05-13 | $1.91M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $774.00K derived: sum of 3 quarters · filed 2025-03-20 | $1.43M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-05 | $774.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.43M 10-Q · filed 2024-11-05 | $1.43M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-06-30 | $774.00K 10-Q · filed 2024-08-06 | $1.43M 10-Q · filed 2024-08-06 | $1.43M derived: sum of 3 quarters · filed 2025-03-20 | $1.43M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-03-31 | $656.00K 10-Q · filed 2024-05-09 | $656.00K derived: sum of 2 quarters · filed 2025-03-20 | $656.00K derived: sum of 3 quarters · filed 2025-03-20 | $656.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |